Team:UCSF/Project

From 2010.igem.org

(Difference between revisions)
 
(47 intermediate revisions not shown)
Line 1: Line 1:
-
<!--- The Mission, Experiments --->
+
{{Template:UCSF/BannerAndNav}}
 +
{{Template:UCSF/WholeBlockStart}}
-
{| style="color:#1b2c8a;background-color:#0c6;" cellpadding="3" cellspacing="1" border="1" bordercolor="#fff" width="62%" align="center"
+
<html>
-
!align="center"|[[Team:UCSF|Home]]
+
<head>
-
!align="center"|[[Team:UCSF/Team|Team]]
+
-
!align="center"|[http://igem.org/Team.cgi?year=2010&team_name=UCSF Official Team Profile]
+
-
!align="center"|[[Team:UCSF/Project|Project]]
+
-
!align="center"|[[Team:UCSF/Parts|Parts Submitted to the Registry]]
+
-
!align="center"|[[Team:UCSF/Modeling|Modeling]]
+
-
!align="center"|[[Team:UCSF/Notebook|Notebook]]
+
-
!align="center"|[[Team:UCSF/Safety|Safety]]
+
-
|}
+
-
=='''Project Description'''==
+
<script>
 +
var Numbering="N3 N3-1";
 +
</script>
-
    Natural killer (NK) cells of the immune system identify cancer and virally-infected cells and kill them. These potent killers travel throughout the body, recognizing proteins and other molecules on the surface of cells. In order to differentiate between healthy and diseased cells, NK cells use a variety of receptors, which bind to specific ligands at the target cells’ surface. The balance between activating and inhibitory signals will tell the NK cell if the target cell is diseased or healthy, respectively. If the target cell is deemed potentially dangerous, the NK cell grips the target cell tightly and creates an immunological synapse at the site of adhesion. Within this immunological synapse, the NK cell releases cytotoxic granules to kill the target cell without harming any nearby cells allowing for a direct, apoptotic death.
+
<style>
 +
h3{
 +
text-vertical-align:middle;
 +
background-image:url(http://2010.igem.org/wiki/images/3/31/UCSF_meihuabiao.png);
 +
text-indent: 35px;
 +
background-repeat: no-repeat;
 +
color:green;
 +
}
-
    Our team will focus on improving NK cells’ specificity and killing efficiency towards certain cancer types. By using synthetic biology tools and logic gates’ design, we hope to create powerful killing biomachines for the fight against cancer. Our newly engineered synthetic devices would have the potential to enhance current adoptive cell-based immunotherapy for cancer patients.
+
p{
 +
margin-left:35px;
 +
margin-right:35px;
 +
}
 +
</style>
 +
</head>
 +
<body>
-
== '''Overall project''' ==
+
<br>
 +
<h3 style="font-weight:bold;">Project Description</h3>
-
Your abstract
+
<p>The UCSF 2010 iGEM team aims to combat one of the leading causes of death worldwide - cancer. Globally, cancer accounts for nearly 1 of every 8 deaths. The number is projected to rise continuously as 1,530,000 new cancer cases are expected to be diagnosed just this year alone. We attempt to fight cancer by enhancing the immune system’s functions using synthetic biology. Specifically, our goal is to turn natural immune cells into Synthetic Killers that can:</p><br>
 +
<div style="position: relative; left:45px;">
 +
<ul>
 +
<li>Detect cancer cells with <b>Greater Precision</b></li>
 +
<li>Initiate killing responsively through <b>Enhanced Signaling</b></li>
 +
<li>Destroy cancer cells effectively with <b>Better Arsenal</b></li>
 +
</ul>
 +
</div>
 +
<br>
 +
<p>Through our research, we hope to improve cancer therapies that involve the use of immune cells. Successfully engineered Synthetic Killers could be particularly useful for detecting tumors in early stages, which could bring new definition to the current use of immunotherapy. Introducing these Synthetic Killers in the early stages of cancer can prevent the disease from getting worse or even spreading elsewhere in the body.</p>
 +
<p>First, let me tell you a little about the immune system natural response against cancer.</p>
 +
<br>
 +
<h3 style="font-weight:bold;">Introduction to Killer Immune Cells</h3>
 +
<p>In the mammalian immune system, many types of while blood cells with specific functions and responsibilities constantly work to defend the body against disease. There are two types of immune cells that are at the center of the fight against cancer: natural killer (NK) cells and cytotoxic T cells. NK cells are part of the innate immune response and survey the body for any unusual activity before signaling for additional help.  If necessary, the activation of NK cells will then signal for a secondary response in which cytotoxic T cells are called to assist in the removal of the remaining unhealthy/cancerous cells. In this project, we will be referring to these cells as Killer Immune Cells. Both of these types of killer cells go through a similar process from detection to elimination of the cancer cell.</p><br>
-
== '''Project Details'''==
+
<p><b>1 - Detection of Cancer Cells by Killer Immune Cells</b></p>
 +
<p>Killer immune cells scan the body for unhealthy cells, such as cancer. They do this by recognizing and binding specific markers (antigens) on the surface of cells. To be able to differentiate between healthy and cancer cells, killer immune cells use a variety of receptors that bind to specific antigens present in the target cell’s surface. Once the receptors bind their respective antigens they send an activation or inhibitory signal to the inside of the cell. The balance between activating and inhibitory signals tells the killer immune cell if it is in the presence of a cancer or healthy cell, respectively.  If the activation signal predominates the killer immune cell will get ready to eliminate the cancer cell. In case the inhibitory signal is stronger the killer cell knows that it is in the presence of a healthy cell and it will move on to the next target.</p>
 +
<p>When activating receptors in the killer cell bind cancer antigens they send the activating signal to the inside of the cell through an intracellular activation domain. This activation domain recruits and activates kinases, which in turn will activate other proteins and start a series of signaling cascade events that will lead to the formation of a tight junction between the killer cell and the cancer cell called an immune synapse. Conversely, when an inhibitory receptor binds a normal antigen it will activate its intracellular inhibition domain, which will recruit phosphatases. The phosphatases erase the work of kinases and a killing response will not occur, letting the killer cell move on to check the health of other cells (see Figure 1).</p><br>
 +
<div style="position: relative; left:45px;">
 +
<img src="http://2010.igem.org/wiki/images/6/60/Killer_immune_cells_FIG.png" />
 +
</div><br>
 +
<p><b><i>Figure 1</i></b>: Killer cells have a variety of receptors at their cell-surface that bind cancer antigens or normal antigens. The receptors that bind cancer antigens get activated, recruiting and activating kinases, which in turn activate signal cascades that lead to the killing of the cancer cell by the killer immune cell (Diagram on the left). Receptors that bind normal antigens in the target cell will also get activated but instead they recruit and activate phosphatases, which will silence the action of kinases (Diagram on the right). In this case the killer cell spares the target cell and moves on to check the health of other cells.</p><br>
-
=== Part 2 ===
 
 +
<p><b>2 - Immune Synapse Formation and Cytotoxic Granules Release</b></p>
 +
<p>Once a killer cell is activated and an immune synapse is formed, the cytotoxic granules present in killer cells get released to act on the cancer cell (see Figure 2). These cytotoxic granules are rich in killing agents, such as granzymes, and once these agents penetrate the cancer cell membrane they will induce the cancer cell to apoptose (kill itself). The immune synapse, a tight embrace between the cancer and killer cell, limits the spread of the killer cell’s arsenal to neighboring, possibly healthy, cells.</p><br>
 +
<div style="position: relative; left:45px;">
 +
<img src="http://2010.igem.org/wiki/images/9/9d/Immune_Synapse_Fig.png" />
 +
</div><br>
 +
<p><b><i>Figure 2</i></b>: After the killer cell receptor is activated by binding the cancer antigen (1) a series of signaling events lead to the formation of the immune synapse (2). By the time the killer cell is ready to kill the cytotoxic granules recruited to the synapse and released (3). Content from the cytotoxic granules, such as granzymes, acts on the cancer cell and leads the cancer cell to apoptose (4).</p><br>
-
=== The Experiments ===
 
 +
<h3 style="font-weight:bold;">Project Aims: Our goals and motivations</h3><br>
 +
<p>To eliminate cancer more efficiently we thought we could use synthetic biology to engineer synthetic cancer killers that would have improved detection, activation and killing arsenal. For that we would have to modify different steps on the pathway from cancer detection to elimination. Our SYNTHETIC CANCER KILLERS would have:</p><br>
-
=== Part 3 ===
+
<div style="position:relative; left:45px;">
 +
<ul>
 +
<li><a href="http://2010.igem.org/Team:UCSF/Project/Precision"><b>GREATER PRECISION</b></a> in detecting cancer cells</li>
 +
<li><a href="http://2010.igem.org/Team:UCSF/Project/Signaling"><b>STRONGER SIGNALING</b></a> that would lead to a more potent killing response</li>
 +
<li><a href="http://2010.igem.org/Team:UCSF/Project/Arsenal"><b>BETTER ARSENAL</b></a> with new powerful killing agents capable of eliminating cancer cells that had acquire resistance.</li>
 +
</ul>
 +
</div><br>
-
==''' Results '''==
+
<p>To learn how we approach these different challenges continue reading on our sub-projects wiki pages.</p><br><br>
 +
</body>
 +
</html>
 +
{{Template:UCSF/WholeBlockEnd}}
__NOTOC__
__NOTOC__

Latest revision as of 00:27, 28 October 2010


Project Description

The UCSF 2010 iGEM team aims to combat one of the leading causes of death worldwide - cancer. Globally, cancer accounts for nearly 1 of every 8 deaths. The number is projected to rise continuously as 1,530,000 new cancer cases are expected to be diagnosed just this year alone. We attempt to fight cancer by enhancing the immune system’s functions using synthetic biology. Specifically, our goal is to turn natural immune cells into Synthetic Killers that can:


  • Detect cancer cells with Greater Precision
  • Initiate killing responsively through Enhanced Signaling
  • Destroy cancer cells effectively with Better Arsenal

Through our research, we hope to improve cancer therapies that involve the use of immune cells. Successfully engineered Synthetic Killers could be particularly useful for detecting tumors in early stages, which could bring new definition to the current use of immunotherapy. Introducing these Synthetic Killers in the early stages of cancer can prevent the disease from getting worse or even spreading elsewhere in the body.

First, let me tell you a little about the immune system natural response against cancer.


Introduction to Killer Immune Cells

In the mammalian immune system, many types of while blood cells with specific functions and responsibilities constantly work to defend the body against disease. There are two types of immune cells that are at the center of the fight against cancer: natural killer (NK) cells and cytotoxic T cells. NK cells are part of the innate immune response and survey the body for any unusual activity before signaling for additional help. If necessary, the activation of NK cells will then signal for a secondary response in which cytotoxic T cells are called to assist in the removal of the remaining unhealthy/cancerous cells. In this project, we will be referring to these cells as Killer Immune Cells. Both of these types of killer cells go through a similar process from detection to elimination of the cancer cell.


1 - Detection of Cancer Cells by Killer Immune Cells

Killer immune cells scan the body for unhealthy cells, such as cancer. They do this by recognizing and binding specific markers (antigens) on the surface of cells. To be able to differentiate between healthy and cancer cells, killer immune cells use a variety of receptors that bind to specific antigens present in the target cell’s surface. Once the receptors bind their respective antigens they send an activation or inhibitory signal to the inside of the cell. The balance between activating and inhibitory signals tells the killer immune cell if it is in the presence of a cancer or healthy cell, respectively. If the activation signal predominates the killer immune cell will get ready to eliminate the cancer cell. In case the inhibitory signal is stronger the killer cell knows that it is in the presence of a healthy cell and it will move on to the next target.

When activating receptors in the killer cell bind cancer antigens they send the activating signal to the inside of the cell through an intracellular activation domain. This activation domain recruits and activates kinases, which in turn will activate other proteins and start a series of signaling cascade events that will lead to the formation of a tight junction between the killer cell and the cancer cell called an immune synapse. Conversely, when an inhibitory receptor binds a normal antigen it will activate its intracellular inhibition domain, which will recruit phosphatases. The phosphatases erase the work of kinases and a killing response will not occur, letting the killer cell move on to check the health of other cells (see Figure 1).



Figure 1: Killer cells have a variety of receptors at their cell-surface that bind cancer antigens or normal antigens. The receptors that bind cancer antigens get activated, recruiting and activating kinases, which in turn activate signal cascades that lead to the killing of the cancer cell by the killer immune cell (Diagram on the left). Receptors that bind normal antigens in the target cell will also get activated but instead they recruit and activate phosphatases, which will silence the action of kinases (Diagram on the right). In this case the killer cell spares the target cell and moves on to check the health of other cells.


2 - Immune Synapse Formation and Cytotoxic Granules Release

Once a killer cell is activated and an immune synapse is formed, the cytotoxic granules present in killer cells get released to act on the cancer cell (see Figure 2). These cytotoxic granules are rich in killing agents, such as granzymes, and once these agents penetrate the cancer cell membrane they will induce the cancer cell to apoptose (kill itself). The immune synapse, a tight embrace between the cancer and killer cell, limits the spread of the killer cell’s arsenal to neighboring, possibly healthy, cells.



Figure 2: After the killer cell receptor is activated by binding the cancer antigen (1) a series of signaling events lead to the formation of the immune synapse (2). By the time the killer cell is ready to kill the cytotoxic granules recruited to the synapse and released (3). Content from the cytotoxic granules, such as granzymes, acts on the cancer cell and leads the cancer cell to apoptose (4).


Project Aims: Our goals and motivations


To eliminate cancer more efficiently we thought we could use synthetic biology to engineer synthetic cancer killers that would have improved detection, activation and killing arsenal. For that we would have to modify different steps on the pathway from cancer detection to elimination. Our SYNTHETIC CANCER KILLERS would have:



To learn how we approach these different challenges continue reading on our sub-projects wiki pages.